Vita Life SciencesASX:VLS 83 Return-on-Tangible-Asset is 14.26% as of Dec. 2025, which is 13% above its 10-year median of 12.60. GuruFocus rates ASX:VLS with a GF Score™ of 83/100 and a GF Value™ of A$2.48 (Fairly Valued). The stock has 1 warning sign investors should review. Among 1,005 Drug Manufacturers companies, Vita Life Sciences ranks better than 86.47% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Vita Life Sciences's annualizedNet Income for the quarter that ended in Dec. 2025 was A$11.19 Mil. Vita Life Sciences's average total tangible assets for the quarter that ended in Dec. 2025 was A$78.47 Mil. Therefore, Vita Life Sciences's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 was 14.26%.
The historical rank and industry rank for Vita Life Sciences's Return-on-Tangible-Asset or its related term are showing as below:
ASX:VLS'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 7.12 Med: 12.6 Max: 19.66
Current: 13.68
During the past 13 years, Vita Life Sciences's highest Return-on-Tangible-Asset was 19.66%. The lowest was 7.12%. And the median was 12.60%.
ASX:VLS's Return-on-Tangible-Asset is ranked better than 86.47% of 1005
companies
in the Drug Manufacturers industry
Industry Median: 3.15
vs ASX:VLS: 13.68
Vita Life Sciences (ASX:VLS) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Vita Life Sciences Return-on-Tangible-Asset Related Terms
Vita Life Sciences Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Vita Life Sciences's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:VLS vs ZTS, UTHR: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Vita Life Sciences's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vita Life Sciences Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vita Life Sciences's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Vita Life Sciences's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
What does a Return-on-Tangible-Asset of 14.26% mean?
Vita Life Sciences (ASX:VLS) has a Return-on-Tangible-Asset of 14.26% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Vita Life Sciences and its competitors. This is 13% above median its historical median of 12.60. Over the past decade, Vita Life Sciences' Return-on-Tangible-Asset has ranged from 7.12 to 19.66. According to the industry distribution chart, Vita Life Sciences ranks #136 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 13.5%.
Is Vita Life Sciences' Return-on-Tangible-Asset too high?
Vita Life Sciences' current Return-on-Tangible-Asset of 14.26% is 13% above median its 10-year median of 12.60. Over the past 10 years, this metric has ranged from a low of 7.12 to a high of 19.66. The Drug Manufacturers industry median Return-on-Tangible-Asset is 3.15. Vita Life Sciences' value of 14.26% is 352.7% above this industry median. Based on the distribution chart, Vita Life Sciences ranks #136 out of 1005 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Vita Life Sciences has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vita Life Sciences' Return-on-Tangible-Asset compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vita Life Sciences ranks #136 out of 1005 companies for Return-on-Tangible-Asset. This places Vita Life Sciences in the top 14% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 3.15. Vita Life Sciences' value of 14.26% is 352.7% above this benchmark. Historically, Vita Life Sciences' own Return-on-Tangible-Asset has ranged from 7.12 to 19.66 over the past decade. While the company's 10-year median is 12.60 vs. the industry median of 3.15, Vita Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.15, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vita Life Sciences's current Return-on-Tangible-Asset of 14.26% is 352.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Vita Life Sciences and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vita Life Sciences's current Return-on-Tangible-Asset is 14.26%, which is 13% above median its own 10-year median of 12.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vita Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Vita Life Sciences (ASX:VLS) is currently considered Fairly Valued. The stock's GF Value™ is A$2.48, compared to a current price of A$2.50 — trading 0.8% above its estimated fair value. The current Return-on-Tangible-Asset is 14.26%, which is 13% above median its 10-year median of 12.60 and 352.7% above the Drug Manufacturers industry median of 3.15. Vita Life Sciences' overall GF Score™ is 83/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Vita Life Sciences (ASX:VLS), the current Return-on-Tangible-Asset is 14.26% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vita Life Sciences (ASX:VLS) Overvalued in 2026?
Based on GuruFocus' analysis, Vita Life Sciences stock appears to be overvalued.
The current stock price of A$2.50 is trading 0.8% above its estimated GF Value™ of A$2.48.
GuruFocus considers Vita Life Sciences to be Fairly Valued.
Key valuation signals for ASX:VLS:
Return-on-Tangible-Asset: 14.26% (13% above median its 10-year median of 12.60)
GF Value™: A$2.48 vs. price of A$2.50 (0.8% above fair value)
Industry Position: 352.7% above the Drug Manufacturers median (#136 of 1005)
No single metric tells the full story. See the ASX:VLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vita Life Sciences Ltd is an Australian-based pharmaceutical and healthcare company involved in formulating, packaging, selling, and distributing vitamins and supplements. It produces a wide range of premium supplements, vitamins, minerals, herbs, and superfoods catered to all age categories and health conditions. The company markets its products through pharmacies and health food stores under the VitaHealth, VitaScience, and Herbs of Gold brands throughout the Asia-Pacific region. Vita Life Sciences has two operating segments: VMS Operational, which generates maximum revenue, and VMS Investments. Geographically, the Group generates maximum revenue from Malaysia and Singapore, and the rest from Australia, and China and Vietnam.
83GF Score
Get the complete analysis for ASX:VLS
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:VLS has been successfully added to your 
